NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MILPREM-200 is an oral tablet combining conjugated estrogens with meprobamate, a fixed-dose combination product historically used for menopausal symptom relief with anxiolytic support. This is a legacy combination product in pre-launch status from Bausch Health. The mechanism involves estrogen replacement therapy paired with a sedative anxiolytic to address vasomotor and mood symptoms in menopausal women.
Pre-Launch
Pre-launch status indicates early-stage commercial build-out with limited team infrastructure; career opportunity exists in establishing go-to-market strategy for a niche hormonal combination product.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MILPREM-200 offers early-stage career exposure to product launch dynamics and legacy brand repositioning within Bausch Health's portfolio. However, limited job postings (0 linked roles) and pre-launch status indicate a smaller team footprint with constrained growth trajectory compared to blockbuster therapeutics.
Brand ManagerProduct Manager
Worked on MILPREM-200 at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.